| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC12302 | CCR2 antagonist 3 Featured | CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist. |
|
| DC11204 | CCR6 inhibitor 35 | CCR6 inhibitor 35 is a potent and selective CCR6 inhibitor with IC50 of 6.0 nM (hCCR6). |
|
| DC20876 | CCT 068127 | CCT 068127 (CCT68127) is a novel potent inhibitor of CDK2 and CDK9 with IC50 of 10 and 90 nM for CDK2/E and CDK9/T, respectively. |
|
| DC8776 | CCT 137690 | CCT 137690 is a potent inhibitor of Aurora kinases (IC50 values are 0.015, 0.019 and 0.025 μM at Aurora A, Aurora C and Aurora B respectively). |
|
| DC20875 | CCT 365623 hydrochloride | CCT 365623 (CCT365623) hydrochloride is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM. |
|
| DC20874 | CCT 365623 | CCT 365623(CCT365623, CCT-365623) is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM. |
|
| DC7803 | CCT007093 Featured | CCT007093 is a potent PPM1D (WIP1) inhibitor with IC50 of 8.4 μM. |
|
| DC22464 | CCT-018159 | CCT-01815 is a novel potent inhibitor of Hsp90 ATPase activity with IC50 of 7.1 uM. |
|
| DC12283 | CCT020312 | CCT020312 is capable of delivering potent, and eukaryotic initiation factor 2-alpha kinase 3 (EIF2AK3) selective, proliferation control and also is an activator of RNA-like endoplasmic reticulum kinase (PERK). |
|
| DC20872 | CCT-031374 | CCT-031374 is a selective β-catenin signaling inhibitor with IC50 of 6.1 uM. |
|
| DC23168 | CCT128930 | CCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2), 28-fold selectivity over the closely related PKA. |
|
| DC23163 | CCT129202 Featured | CCT129202 is a potent, selective, ATP-competitive pan-Aurora kinase inhibitor with IC50 of 42, 198 and 227 nM for Aurora A, Aurora B and Aurora C, respectively. |
|
| DC10005 | CCT196969 Featured | CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. |
|
| DC23828 | CCT241161 | CCT241161 is a potent pan-RAF inhibitor with IC50 of 30, 15 and 6 nM for BRAF, V600E-BRAF and C-RAF, also potently inhibits SRC and LCK (IC50=10 and 3 nM, respectively).. |
|
| DC9399 | CCT241533 (hydrochloride) | CCT241533 Hcl is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM; shows minimal cross-reactivity against a panel of kinases at 1 uM. |
|
| DC10911 | CCT241736 Featured | CCT241736 is a novel, orally bioavailable Dual FLT3-Aurora Kinase Inhibitor. |
|
| DC8324 | CCT244747 Featured | CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies. |
|
| DC10498 | CCT251236 Featured | CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC50 of 19 nM for inhibition of HSF1-mediated HSP72 induction. |
|
| DC9968 | CCT251545 Featured | CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with IC50 value of 5 nM. |
|
| DC9969 | CCT251921 | CCT251921 is a potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. (IC50 data: CDK8:=2.3 nM; CDK19 = 2.6 nM). |
|
| DC11679 | CCT-367766 Featured | CCT367766 is a potent and the third generation heterobifunctional and PROTAC-based pirin targeting protein degradation probe (PDP), depletes pirin protein expression at low concentration. CCT367766 exhibits a moderate affinity for the CRBN-DDB1 complex with an IC50 value of 490 nM. CCT367766 reveals a good affinity for the recombinant pirin and CRBN with Kd values of 55 nM and 120 nM, respectively. CCT367766 provides a potential chemical tool to study a largely unexplored protein[1]. |
|
| DC10206 | CCX140 | CCX140 is a potent CCR2 antagonist. |
|
| DC12549 | CCX-354 | CCX-354 (GSK-2941266, CCX354-C, CCX354) is a potent, selective, orally-available CCR1 antagonist for the treatment of inflammatory diseases such as rheumatoid arthritis (RA).. |
|
| DC10955 | CD12681 | CD12681 (CD-12681) is a potent, selective RORγ inverse agonist with IC50 of 19 nM, displays no activity against a panel of nuclear receptors (RORα, RARγ, LXRβ, PPARγ and VDR). |
|
| DC20332 | CD38 inhibitor 78c Featured | CD38 inhibitor 78c is a potent, specific, reversible CD38 inhibitor with Ki of 14.5 nM for recombinant human CD38. |
|
| DC10491 | CD437 Featured | CD437 is a synthetic retinoid that is an RARγ-selective agonist. It displays RARγ-dependent and -independent effects on differentiation and apoptosis. |
|
| DC20877 | S8 | Cdc25 inhibitor S8 is an anti-fungal small molecule that inhibits cdc25 phosphatase with Ki of 140 uM. |
|
| DC10909 | BN82002 Featured | CDC25 Phosphatase Inhibitor I, BN82002, is a cell-permeable ortho-hydroxybenzylamino compound that has been reported to display antitumor properties. |
|
| DC21877 | Cdc7 inhibitor | Cdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays.. |
|
| DC10433 | CDD3505 | CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity. |
|
